Comparison of the Novel Thrombolytic Constitutively Active ADAMTS13 With Clinical Thrombolytics in a Murine Stroke Model.

FeCl 3 dMCAo was used due to its formation of platelet- and VWF-rich, fibrin-poor thrombi 13 , 18 that are largely resistant to r-tPA, albeit alongside a slight trend to improvement following r-tPA treatment, 18 , 19 consistent with the findings here. r-tPA’s variant, TNK, had comparable effects on stroke outcome to r-tPA in our hands, which also holds true for lesion volume in a fibrin-rich dMCAo model. 10 As anticipated, caADAMTS13 exhibited improved, or trend

also in 4,078 other papers